Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PRQR with free AI briefings, catalyst countdowns, and dilution alerts.

PRQR · ProQR Therapeutics N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$117.1M Cash on Hand
28.7mo Cash Runway
2.7% Short Interest
$7.56 Analyst Target (9)
Follow PRQR by email Get an email when PRQR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PRQR, unsubscribe in one click. Privacy

📣 What PRQR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sepofarsen Leber Congenital Amaurosis 10 Phase 2/3 · NCT03913143 Active not recruiting
QR-010 Cystic Fibrosis Phase 1/2 · NCT02532764 Completed
QR-1123 Autosomal Dominant Retinitis Pigmentosa Phase 1/2 · NCT04123626 Active not recruiting
QR-421a Retinitis Pigmentosa Phase 1/2 · NCT03780257 Completed
QR-504a Fuchs Endothelial Corneal Dystrophy Phase 1 · NCT05052554 Withdrawn

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PRQR holds $117.1M in cash and short-term investments and burns about $12.3M/quarter from operations, an estimated runway of 28.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRQR files for a raise →

👥 Who Owns PRQR

Insiders 2.3% Other 5%+ holders 35.5% Institutions (78 holders) 54.4% Public and other holders 7.8%
HolderTypeShares% of sharesAs of
ELI LILLY & Co 5%+ holder (13G) 21,995,880 20.88% 2026-06-26
Van Herk Investments B.V. 5%+ holder (13D) 15,384,250 14.60% 2026-07-27
Adage Capital Partners GP L.L.C. Institution (13F) 9,015,897 8.56% 2026-09-30
Aberdeen Group plc Institution (13G, 5%+) 8,932,507 8.48% 2026-06-30
PATRICK JOHAN HENDRIK KROL Institution (13G, 5%+) 5,528,862 5.25% 2026-07-15
Privium Fund Management B.V. Institution (13F) 5,467,149 5.19% 2026-09-30
Affinity Asset Advisors, Llc Institution (13F) 4,970,074 4.72% 2026-09-30
Ikarian Capital, LLC Institution (13F) 3,425,930 3.25% 2026-09-30
683 Capital Management LLC Institution (13F) 2,050,000 1.95% 2026-09-30
Sphera Funds Management Ltd. Institution (13F) 1,757,458 1.67% 2026-09-30
Kynam Capital Management, LP Institution (13F) 1,566,317 1.49% 2026-09-30
Lynx1 Capital Management Lp Institution (13F) 1,562,093 1.48% 2026-09-30

Share count 105,361,064 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-07-31
filed 2026-08-03
de Boer Daniel Anton
Purchase (P) 200,000 $1.77 500,000
2026-07-17
filed 2026-07-21
Filius Bart
Purchase (P) 150,000 $1.72 300,000
2026-07-09
filed 2026-07-13
de Boer Daniel Anton
Purchase (P) 150,000 $1.74 300,000
2026-07-07
filed 2026-07-08
de Boer Daniel Anton
Purchase (P) 150,000 $1.59 150,000
2026-06-02
filed 2026-06-03
Hinsch Gylvin Lykke
Option award (A) 14,495 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full PRQR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRQR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.